Janssen Diagnostics, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has earned Food and Drug Administration (FDA) clearance for the Idylla Respiratory (IFV-RSV) panel, a molecular diagnostic test developed in partnership with Biocartis. This test facilitates the diagnosis of infection caused by respiratory syncytial virus (RSV) and influenza virus (IFV) through the detection of a wide array of pathogens, including influenza A and B, influenza B subtype H1, influenza A subtype H3, influenza A subtype 2009 H1, H275Y mutation of influenza A subtype 2009 H1, and RSV types A and B. The assay uses samples from nasopharyngeal swabs in viral transport media of adult and pediatric patients and is processed on Biocartis’ Idylla system, a fully automated multiplex polymerase chain reaction diagnostic platform. This platform provides results for the IFV-RSV panel in approximately 50 minutes with less than 2 minutes hands-on time. This is the first FDA clearance Biocartis has received on the Idylla system, marking a milestone for the Belgium-based company.